Skip to main content
OpenTrials
Completed

NCT Number: NCT02335307

Implementing Genomics in Practice (IGNITE) Proof of Concept Study: Genotyping in Family Medicine Clinics

This study will examine the effect of having genotype information on pain management and pain control for patients treated in family medicine clinics. This study will also examine physician-perceived usefulness of genotype information. Patients will be enrolled from family medicine clinics serving as either implementation sites or control sites. Patients from implementation sites will undergo genotyping, while those from control sites will not by genotyped.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Archer Family Health Care, Archer, Florida, United States

Loading trial locations.

About this study

Codeine and tramadol are opioid analgesics that depend on cytochrome P450 2D6 (CYP2D6) for bioactivation to morphine and O-desmethyltramadol, respectively. Morphine and O-desmethyltramadol have much greater affinity for the opioid receptor and thus are more powerful analgesics.

Individuals with genotypes associated with low CYP2D6 activity (poor metabolizers) are unable to convert sufficient amounts of codeine or tramadol to their active metabolites and may fail to derive sufficient pain relief. At the opposite extreme, individuals with genotypes associated with increased CYP2D6 activity (ultra-rapid metabolizers) are at risk for serious toxicity with usual codeine or tramadol doses.

The CYP2D6 genotype also has implications for response to other drugs, such as tricyclic antidepressants (TCAs), which are commonly used for neuropathic pain.

Patients will be recruited from family medicine clinics, serving as either implementation sites or control sites. Patients from implementation sites will undergo CYP2D6 genotyping, with results placed in the medical record to assist with prescribing of pain medications. Pain medications prescribed from baseline to 3 months will be assessed through medical record review. A pain assessment questionnaire will be administered to patients enrolled from both sites at baseline and 3 months.

At the end of the study, a 20-item survey will be administered to physicians at the implementation sites. We will assess whether having CYP2D6 genotype results is useful to inform prescribing decisions for pain medication from the physician's perspective.

We will also assess medicines prescribed to patients enrolled from both sites over the 12-month period after enrollment from medical record review and determine the number of patients who were prescribed a medication that has genetic information in its FDA-approved label.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Treated in family medicine clinic
  • History of pain for at least 3 months
  • Prescribed medication for pain relief

Exclusion criteria

  • Pain for less than 3 months
  • Not currently prescribed any medication for pain

Treatment and study plan

CYP2D6 genotyping

Genetic

CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.

Pain assessment questionnaire

Other

A pain assessment questionnaire will be administered at baseline and 3 months.

Other names: PROMIS questionnaire

Physician assessment

Other

20-item survey administered to physicians treating patients enrolled in the study

Primary outcomes

  1. Change in overall pain score (Patient Reported Outcomes Measurement Information System (PROMIS)

    Time frame: Change from baseline to 3 months

    Patient Reported Outcomes Measurement Information System (PROMIS) measures will be used to assess pain intensity, physical functioning, and emotional functioning. There are 10 subscales on the PROMIS questionnaire that address the domains of pain, pain functioning, and emotional functioning. At least 4 (and up to 30) items are used to derive a score for each subscale. A computer adaptive version of the questionnaire based on item response theory will be used to administer the survey. A score of 0 to 100 based on survey responses will be resulted for each subscale.

Secondary outcomes

  1. Change in pain medication

    Time frame: Change from baseline to 3 months

    Change in pain medication will be evaluated in several manners: change in the opiate prescribed, change from an opiate to a non-opiate; and change in dose of the opiate prescribed

  2. Change in pain score of pain intensity (Patient Reported Outcomes Measurement Information System (PROMIS) subscale)

    Time frame: Change from baseline to 3 months

    Patient Reported Outcomes Measurement Information System (PROMIS) subscale for pain intensity, with the score ranging from 0 to 100 resulting.

  3. Change in pain score of physical functioning (Patient Reported Outcomes Measurement Information System (PROMIS) subscale)

    Time frame: Change from baseline to 3 months

    Patient Reported Outcomes Measurement Information System (PROMIS) subscales for physical functioning include pain function, pain interference, pain behavior, sleep disturbance, and sleep-related impairment. A score of 0 to 100 based on survey responses will be resulted for each subscale.

  4. Change in pain score of emotional functioning

    Time frame: Change from baseline to 3 months

    Patient Reported Outcomes Measurement Information System (PROMIS) subscales for emotional functioning include fatigue, anxiety, depression, and anger. A score of 0 to 100 based on survey responses will be resulted for each subscale.

  5. Physician perceived usefulness of genetic information (survey)

    Time frame: 3 months

    Survey will be administered to physicians with patients in the study to assess the effect of having genotype information on their prescribing decisions.

  6. Medications prescribed with pharmacogenetic implications (Percent of patients with at least one other drug (besides an opioid) where genotype information might be useful for prescribing)

    Time frame: 12 months

    Percent of patients with at least one other drug (besides an opioid) where genotype information might be useful for prescribing

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Collaborators

  • National Human Genome Research Institute (NHGRI)

Registry information

Acronym: IGNITE

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Jan 9, 2015
Registry last updated
Jun 6, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.